EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Cost-Effectiveness of TAVR Compared With Clinical Surveillance in Patients with Asymptomatic Severe Aortic Stenosis in the United States

Philippe Généreux, Matthew R Reynolds, Marcella A Kelley, Christin Thompson, Suzanne J Baron

Value in Health · 2026-07 · 29 (7) · 1171-1179

DOI: 10.1016/j.jval.2026.02.005 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Value in Health, 2026-07. Verfasst von Philippe Généreux und 4 weiteren Autor:innen. Beteiligte Einrichtung: Morristown Medical Center, Morristown, NJ, USA. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Edwards Lifesciences Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: The EARLY TAVR trial demonstrated improved clinical outcomes for patients with asymptomatic severe aortic stenosis (aSAS) treated with transcatheter aortic valve replacement (eTAVR) compared with clinical surveillance (CS). The cost-effectiveness of an eTAVR strategy for patients with aSAS in the United States is unknown. METHODS: A Markov model with 30-day cycles was developed from the US healthcare payor perspective to estimate the cost-effectiveness of eTAVR vs CS over a lifetime horizon. Inputs for population characteristics and health outcomes were derived from the EARLY TAVR trial. Costs were derived from US Medicare reimbursement rates. Probabilistic and deterministic sensitivity analyses were performed to evaluate the effect of parameter uncertainty on model output. RESULTS: When compared with CS, eTAVR was associated with 0.21 additional life-years (LY) and 0.24 additional quality-adjusted life-years over a lifetime because of more time spent in the alive and well health state with eTAVR. Lifetime costs were estimated to be $8812 lower, due primarily to reductions in costs associated with the AVR procedure, stroke, and heart failure hospitalizations. Accordingly, eTAVR was projected to be economically dominant over CS. In probabilistic sensitivity analysis, a large majority of iterations (95.9%) produced cost-effective results ($100 000 threshold) for eTAVR versus CS, with most simulations (90.3%) showing dominance, confirming the robustness of the base-case results. These findings were consistent over a variety of scenario analyses. CONCLUSIONS: An eTAVR strategy for the treatment of aSAS may be a cost-saving approach for US healthcare payors, when compared with CS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic Valve StenosisTranscatheter Aortic Valve ReplacementHumansCost-Benefit AnalysisCost-Effectiveness AnalysisUnited StatesMarkov ChainsQuality-Adjusted Life YearsSeverity of Illness IndexFemaleModels, EconomicMaleTreatment OutcomeAged, 80 and overAged

Stichwörter der Autor:innen

asymptomatic severe aortic stenosisclinical surveillancecost-effectivenesseconomic modeltranscatheter aortic valve replacement

Autor:innen und Institutionen

  • Morristown Medical Center, Morristown, NJ, USA.
  • Lahey Hospital & Medical Center, Burlington, MA, USA; Baim Institute For Clinical Research, Boston, MA, USA.
  • Edwards Lifesciences, Irvine, CA, USA.
  • Baim Institute For Clinical Research, Boston, MA, USA; Massachusetts General Hospital, Boston, MA, USA. Electronic address: sbaron@partners.org.

Förderung

  • Edwards Lifesciences Corporation

Zitieren

APA

Généreux, P., Reynolds, M. R., Kelley, M. A., Thompson, C., & Baron, S. J. (2026). Cost-Effectiveness of TAVR Compared With Clinical Surveillance in Patients with Asymptomatic Severe Aortic Stenosis in the United States. Value in Health, 29(7), 1171-1179. https://doi.org/10.1016/j.jval.2026.02.005

Vancouver

Généreux P, Reynolds MR, Kelley MA, Thompson C, Baron SJ. Cost-Effectiveness of TAVR Compared With Clinical Surveillance in Patients with Asymptomatic Severe Aortic Stenosis in the United States. Value in Health. 2026;29(7):1171-1179. doi:10.1016/j.jval.2026.02.005

BibTeX
@article{Gnreux2026,
  author = {Généreux, Philippe and Reynolds, Matthew R and Kelley, Marcella A and Thompson, Christin and Baron, Suzanne J},
  title = {Cost-Effectiveness of TAVR Compared With Clinical Surveillance in Patients with Asymptomatic Severe Aortic Stenosis in the United States},
  journal = {Value in Health},
  year = {2026},
  volume = {29},
  number = {7},
  pages = {1171--1179},
  doi = {10.1016/j.jval.2026.02.005}
}
Kostenlos starten →